Immunotherapy Archives

autoimmune disorder eosinophilic esophagitis allergy milk calypso biotech

News and Trends 20 Feb 2019

Inflammatory Disease Treatment Backed by €20M Series A

The Swiss company Calypso Biotech has raised a sizeable €20M to fund its immunotherapy for an allergy-related inflammatory disease. The Series A round will help to develop Calypso’s antibody treatment for eosinophilic esophagitis, a condition where patients have an inflamed esophagus and difficulty swallowing. This condition is often linked with allergies to food, such as […]

February 20, 2019 - 2 minutesmins - By Jonathan Smith

grey wolf therapeutics cancer immunotherapies

News and Trends 11 Feb 2019

Series A to Fund Therapy That Exposes Cancer to Immune System

The UK biotech Grey Wolf Therapeutics has raised €11.4M (£10M) to fuel the development of a cancer therapy that flushes tumor cells out of hiding from the immune system. Many approved cancer immunotherapies, such as CAR-T cell therapy and checkpoint inhibitors, have made a big difference for many people with cancer. However, a common problem with […]

February 11, 2019 - 2 minutesmins - By Jonathan Smith

morphosys genmab janssen cancer immunotherapy

News and Trends 28 Jan 2019

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after the US District Court of Delaware declared three of its cancer immunotherapy patents invalid. MorphoSys began the dispute over Darzalex (daratumumab), Genmab and Janssen’s approved antibody therapy for the blood cancer multiple myeloma. MorphoSys alleged that Darzalex infringed on three of […]

January 28, 2019 - 3 minutesmins - By Dani Bancroft

Philogen cancer immunotherapy antibody pharma t cell

News and Trends 25 Jan 2019

Swiss-Italian Biotech Bags Antibody Deals with Three Big Pharma

The Swiss-Italian company Philogen has announced three different partnerships with Novartis, Celgene, and Janssen to develop new forms of immunotherapy and small molecule drugs. Philogen develops immunocytokines, which are antibodies that are fused with proteins that modify the immune system to fight diseases such as cancer. For example, this treatment can bind to tumors and activate […]

January 25, 2019 - 2 minutesmins - By Jonathan Smith

sanofi biomunex cancer therapy bispecific antibodies 1

News and Trends 15 Jan 2019

Sanofi Obtains License for French Company’s Antibody Engineering Platform

Sanofi has signed a licensing deal with French biotech Biomunex, whose antibody technology has the potential to develop new immunotherapy treatments for cancer and infectious diseases. Sanofi will give Biomunex an upfront payment, along with further installments upon achieving key development milestones. The amounts have not been disclosed. Biomunex is able to make a wide variety […]

January 15, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 7 Jan 2019

Sanofi Invests €80M in mRNA Cancer Vaccine Company

Sanofi is to make an €80M equity investment in the German biotech BioNTech, and the two have agreed to co-develop a cancer vaccine based on injecting messenger RNA into solid tumors. This agreement is an extension of Sanofi and BioNTech’s collaboration, which began in 2015. The two companies will continue to co-develop and co-commercialize a candidate […]

January 7, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 20 Dec 2018

Personalized Immunotherapy for Brain Cancer Succeeds in Clinical Trials

A European trial has proved the feasibility and efficacy of treating cancer with a personalized immunotherapy tailored to each patient. The phase I/II trial, run across six European centers, tested a combination of two personalized vaccines in patients with glioblastoma, an aggressive form of brain cancer. The first vaccine was designed to immunize the patients […]

December 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Dec 2018

Scientists Repurpose Skin Cells to Fight Cancer

Researchers have reprogrammed skin cells to make them behave like immune cell sentinels called dendritic cells, which can recruit the immune system to fight tumors. This discovery makes a step toward better cancer immunotherapy. “We are merging two different areas of research,” Carlos-Filipe Pereira, from Lund University, Sweden, said to me. “One of them is […]

December 10, 2018 - 3 minutesmins - By Jonathan Smith

argenx llama inspired antibodies cover cancer immunotherapy

News and Trends 5 Dec 2018

Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal

Autoimmune disease and acute myeloid leukemia may have a llama-inspired antibody treatment one day. The Dutch company argenx’s antibodies have shown positive results in clinical trials, and have attracted Janssen into a collaboration to advance their use in cancer immunotherapy. In a phase II trial, the company’s lead antibody, efgartigimod, reduced the number of bleeding […]

December 5, 2018 - 3 minutesmins - By Jonathan Smith

News and Trends 30 Nov 2018

Update: UK Biotech Scores £5M Series A to Boost Next-Generation Cancer Antibodies

Update (30/11/2018): IGEM Therapeutics has increased the total raised in Series A to £5M (€5.6M) with the participation of two new investors, Alsa Holdings and UCL Technology Fund. The funding will go towards the development of a new generation of antibody drugs for cancer. Published on 20/06/2017 IGEM Therapeutics has raised £2M (€2.3M) in Series A […]

November 30, 2018 - 2 minutesmins - By Melanie De Almeida

den bosch netherlands lava therapeutics cancer immunotherapy

Startup Scout 23 Nov 2018

This Biotech Arms Tumor-Busting Cells to Treat Cancer

In the medieval city of ‘s-Hertogenbosch, the Netherlands, Lava Therapeutics is developing a cancer immunotherapy that arms a rare type of immune cell called gamma delta T cells. Mission: Develop antibodies that recruit innate immune cells near tumors and activate them to kill cancer cells. T cells are immune cells that have a strong potential […]

November 23, 2018 - 3 minutesmins - By Jonathan Smith

More News! 22 Nov 2018

First Drug for Rare Inflammation Syndrome Approved by FDA

The FDA has approved the first drug for the treatment of a rare condition in which the body produces too many active immune cells, developed in a Swiss-Swedish partnership. The antibody drug, emapalumab, is approved to treat primary hemophagocytic lymphohistiocytosis. This condition is a rare, often fatal syndrome in which the immune system produces too […]

November 22, 2018 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Inflammatory Disease Treatment Backed by €20M Series A

Series A to Fund Therapy That Exposes Cancer to Immune System

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

Swiss-Italian Biotech Bags Antibody Deals with Three Big Pharma

Sanofi Obtains License for French Company’s Antibody Engineering Platform

Sanofi Invests €80M in mRNA Cancer Vaccine Company

Personalized Immunotherapy for Brain Cancer Succeeds in Clinical Trials

Scientists Repurpose Skin Cells to Fight Cancer

Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal

Update: UK Biotech Scores £5M Series A to Boost Next-Generation Cancer Antibodies

This Biotech Arms Tumor-Busting Cells to Treat Cancer

First Drug for Rare Inflammation Syndrome Approved by FDA

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!